Centanafadine Enters Schedule III: ADHD Indication and Place in Therapy

The indication and pharmacology

The FDA-approved indication for Simtriyo is treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged six years and older weighing at least 20 kg. The product consists of oral extended-release capsules. The label does not recommend use in younger children or those weighing less than 20 kg.³

The medication inhibits norepinephrine, dopamine, and serotonin reuptake transporters, and FDA classifies it as a central nervous system stimulant. The label states that its mechanism of action in treating ADHD remains unclear, although its efficacy could be mediated through that transporter activity.⁴

The labeled efficacy program includes placebo-controlled studies in children and adolescents and two adult studies using another formulation. Those studies establish benefit against placebo rather than comparative superiority over existing ADHD medicines.⁵

Its current fit in therapy

Chad’s analysis: Its current fit in therapy will revolve around patients who might benefit from the combined norepinephrine, dopamine, and serotonin reuptake activity. That potential role should be judged through clinical response and tolerability. The pharmacologic profile provides a treatment rationale; it does not identify a validated responder subgroup or establish superior efficacy or safety.⁴⁵

The label carries boxed warnings for suicidal ideation and behaviors in pediatric patients and for abuse, misuse, and addiction. Other considerations include cardiovascular effects, appetite and growth changes, and drug interactions. These issues remain relevant when evaluating its place in an individual patient’s treatment.⁶

Schedule III controls now apply

DEA’s interim final rule placing the active ingredient and its covered salts and isomers in Schedule III became effective October 30, 2026. Comments must be submitted electronically or postmarked by November 30. Hearing requests must be received by that date. Electronic comments close at 11:59 p.m. Eastern Time.¹

The rule assigns drug code 1641 and identifies controls covering registration, security, commercial labeling and packaging, inventories, records, reports, prescriptions, and disposal. Patients possessing the medication under lawful prescriptions are excluded from the listed registration and security requirements.²

FDA issued its approval letter July 24. The letter ties the statutory approval date to DEA’s scheduling publication and requires submission of a scheduling-related labeling supplement before marketing. Scheduling publication alone therefore should not be treated as confirmation of commercial availability.⁷

Translate the classification into pharmacy operations

Chad’s analysis: Follow the product through purchasing, receipt, storage, dispensing, and reconciliation. Confirm that medication records and staff references show the current classification, and assign responsibility for inventory and prescription procedures before processing the first order. Keep the discussion of potential therapeutic fit separate from assumptions about market availability or the meaning of a controlled-substance schedule.